PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
WraSer Pharmaceuticals
 

Company Overview

Contact Info & Offices

Press Releases

WraSer Pharmaceuticals

Press Release

Share      Blog

Receive press releases from WraSer Pharmaceuticals: By Email PDF Version RSS Feeds:

Wraser Pharmaceuticals Announces Publication of White Paper Addressing Opioid Safety


Sharp rises in opioid abuse and overdose rates in the United States over the past two decades have prompted much-needed review of prescription rates and ease of access to controlled substances. Combatting these alarming trends requires assessing which opioids are more addictive and habit-forming than others.

Ridgeland, MS, April 26, 2019 --(PR.com)-- Wraser Pharmaceuticals announces the publication of a White Paper addressing opioid safety.

Sharp rises in opioid abuse and overdose rates in the United States over the past two decades have prompted much-needed review of prescription rates and ease of access to controlled substances. Combatting these alarming trends requires assessing which opioids are more addictive and habit-forming than others and setting standards and guidelines for prescribing that accurately reflect the relative risk of a drug.

Trezix, an oral analgesic used to manage moderate to moderately severe pain, has a lower morphine milligram equivalent dose than stronger opioids such as morphine, hydrocodone, and fentanyl.

In this report the writers present an overview of the safety and usage data for Trezix and similar low dose dihydrocodeine combinations. It is the writers carefully-considered opinion that Trezix should not be regulated as strictly or in the same classification as opioids of morphine-equivalent or higher strength.

“In the age of opioid concerns and disinformation, we wanted to bring attention to alternative options for patients and the physicians who treat them,” said Heath Wray, Wraser’s President and CEO. “We believe Trezix offers a pain-relieving option that is safer for the patient and just as effective as other options for the physicians treating acute pain.”
Contact Information
WraSer Pharmaceuticals
Glenn Willis
601-605-0664
Contact
wraser.com

Click here to view the company profile of WraSer Pharmaceuticals
Click here to view the list of recent Press Releases from WraSer Pharmaceuticals
Promote Your Business